Date: 2015-04-07
Type of information: Series B financing round
Company: Nabriva Therapeutics (Austria)
Investors: Vivo Capital (USA - CA) OrbiMed (USA - NY) EcoR1 Capital (USA - CA) Tavistock Life Sciences (USA - CA) HBM Phase4 Partners (UK) Wellcome Trust (UK) GLSV (Germany) Novartis Venture Fund (Switzerland)
Amount: $120 million
Funding type: series B financing round
Planned used: The initial tranche of $50 million will enable Nabriva to progress its lead product, lefamulin, into clinical phase 3 studies in community-acquired bacterial pneumonia (CABP) and to continue the development of its product pipeline. Nabriva is focused on the discovery and development of pleuromutilin antibiotics. Nabriva’s lead product, lefamulin (BC?3781), is the first systemically available pleuromutilin for human use and is entering pivotal phase 3 studies for the treatment of community-acquired bacterial pneumonia (CABP). Preclinical programs include the Extended Spectrum Pleuromutilins (ESPs), a new generation of antibacterials possessing in vitro activity against urgent and serious bacterial threats identified by the Centers for Disease Control and Prevention (CDC) including carbapenem-resistant Enterobacteriaceae (CRE), while maintaining the antimicrobial spectrum of lefamulin. As such, the ESPs represent much needed development of a novel class of antibacterials, with a unique mechanism of action, directed at addressing this significant unmet medical need.
Others: * On April 7, 2015, Nabriva Therapeutics, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for the treatment of serious infections caused by resistant gram-positive and gram-negative bacteria, announced the successful completion of a $120 million Series B financing. The financing was led by new US based investors Vivo Capital and OrbiMed, and includes EcoR1 Capital, Boxer Capital of Tavistock Life Sciences and new investment from existing investor HBM. Existing investors Phase4 Partners, Wellcome Trust, GLSV and Novartis Venture Fund also participated in the round. Representatives of Vivo Capital and OrbiMed will be joining the Nabriva Supervisory Board.
Therapeutic area: Infectious diseases
